Core Insights - WELL Health Technologies Corp. has announced the completion of a previously announced Series by its majority-owned subsidiary WELLSTAR Technologies Corp. [1] Company Overview - WELL Health Technologies Corp. is a digital healthcare company focused on improving health outcomes through technology [1] - The company aims to empower healthcare practitioners and their patients globally [1] Subsidiary Information - WELLSTAR Technologies Corp. is a majority-owned subsidiary of WELL Health Technologies Corp. [1] - The completion of the Series indicates progress in WELLSTAR's operational and financial strategies [1]

Core Insights - WELL Health Technologies Corp. provides a corporate update on its subsidiary WELLSTAR Technologies, highlighting significant organic and inorganic growth, including a $62 million Series B financing round and strategic acquisitions [2][3][12]. WELLSTAR's Growth and Strategy - WELLSTAR has established itself as Canada's leading digital health platform, driven by organic growth and a growing recurring revenue base [3]. - The company aims for a potential public listing in 2026 while focusing on empowering clinicians with advanced digital tools [3]. OceanMD eReferral Platform - OceanMD has secured a significant eReferral contract, increasing WELLSTAR's Annual Recurring Revenue (ARR) by 16% [4][5]. - The platform now facilitates over 1.7 million eReferrals annually, supported by more than 20,000 physicians and 3,800 clinics across Canada [5][6]. - OceanMD has demonstrated improvements in patient care, including a 12% reduction in unnecessary MRIs and a 20% reduction in surgical wait times [7]. Recent Acquisitions - WELLSTAR has signed agreements to acquire two billing assets expected to generate approximately $4 million in annualized revenue with margins exceeding 20% [9]. - The acquisition of Mutuo Health Solutions enhances WELLSTAR's AI capabilities and aligns its products with clinical workflows [10]. Financial Performance - WELLSTAR reported Q3 revenue of $18.3 million, a 67% increase year-over-year, with organic growth of 26% [11]. - The company's ARR grew 63% year-over-year, indicating a scalable and durable business model [11]. Future Growth Plans - Following the $62 million financing, WELLSTAR is pursuing strategic acquisitions to expand its technology suite and aims for a $100 million annualized run rate [12]. - The company is actively advancing its M&A pipeline and has added a new member to its corporate development team [12].

Core Insights - HEALWELL AI has completed strategic divestments to transition into a pure-play SaaS, services, and AI business focused on preventative healthcare [3][4][5] - The transactions include the sale of non-core assets to WELL Health Technologies Corp. and the establishment of a clinical research joint venture [3][4][5] Transaction Details - HEALWELL sold its Polyclinic Family Medicine and Specialty Clinics Group to WELL Clinics, which has managed these clinics since January 2024 [5][7] - The company divested its 58.66% interest in Mutuo Health Solutions to WELLSTAR Technologies, allowing HEALWELL to concentrate on its core digital healthcare solutions [5][8] - A 50/50 clinical research joint venture was formed with WELL Health Technologies, aimed at advancing clinical research initiatives [5][9] Financial Impact - The transactions are expected to add approximately $9.4 million in cash to HEALWELL's balance sheet upon closing [4] - HEALWELL's revenue run rate is projected to be around $120 million annually, with profitability on an Adjusted EBITDA basis [5] Strategic Focus - The company aims to enhance its focus on high-margin AI and software services for large enterprise customers globally [4][6] - HEALWELL is committed to integrating validated AI solutions with its healthcare software segment to achieve margin expansion and organic growth [6] Governance and Compliance - A special committee was formed to assess the transactions, ensuring fairness and compliance with regulations [10][11][15] - The transactions were approved under the TSX Company Manual and are exempt from certain formal valuation requirements due to their aggregate fair market value [16][17]

Core Insights - WELL Health Technologies Corp. has announced that its majority-owned subsidiary WELLSTAR Technologies Corp. has entered into agreements to complete a Series B funding round [1] Company Overview - WELL Health Technologies Corp. is a digital healthcare company focused on improving health outcomes by leveraging technology to empower healthcare practitioners and their patients globally [1]

Company Overview - WELL Health Technologies Corp. is a digital healthcare company focused on improving health outcomes through technology, operating over 220 clinics and supporting more than 42,000 healthcare providers across Canada and the US [5][6] - WELLSTAR Technologies Corp., a majority-owned subsidiary of WELL, is a leading provider of interoperable technology solutions for healthcare providers in Canada [1][6] Upcoming Conference Participation - WELL and WELLSTAR will participate in the 2025 Cantech Investment Conference on October 9, 2025, in Toronto, Ontario [1][3] - The conference will feature presentations from WELL's CEO Hamed Shahbazi and WELLSTAR's CEO Amir Javidan, focusing on WELL's growth strategy and WELLSTAR's technological capabilities [2][3] Presentation Details - WELL's presentation is scheduled for 1:30 PM EST, while WELLSTAR's presentation will take place at 4:00 PM EST on the same day [3] - The conference is seen as an opportunity to highlight the companies' progress and build relationships with the investment community [3][4] Strategic Focus - WELL aims to reduce administrative burdens, increase provider efficiency, and improve patient care through the use of WELLSTAR and HEALWELL AI technologies [3][4] - The company emphasizes its role as the largest provider of outpatient services in Canada, showcasing its comprehensive healthcare and digital platform [5][6]